Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Disparities in Breast Cancer Response
NCT04741204Phase 4Withdrawn
- Sponsor
- Woman's
- Start
- Sep 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of liquid metformin (Aspargo Labs) in breast cancer, sponsored by Woman's. Planned start Sep 2022; status: withdrawn.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04741204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04741204.